Media Relations News Releases Year: - Any -20202019201820172016 Items per page 102550 Jun 23, 2017 Summary ToggleNovartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Jun 15, 2017 Summary ToggleNovartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years Jun 8, 2017 Summary ToggleNovartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting May 4, 2017 Summary ToggleNovartis exercises exclusive option agreement with Conatus for the treatment of NASH Apr 28, 2017 Summary ToggleNovartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) Apr 24, 2017 Summary ToggleNovartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS Apr 18, 2017 Summary ToggleNovartis expands development programs for NASH through clinical collaboration with Allergan Mar 21, 2017 Summary ToggleNovartis’ Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis Mar 13, 2017 Summary ToggleNovartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Nov 29, 2016 Summary ToggleNovartis Access shares one-year learnings and announces memorandum of understanding with Rwanda Pagination First page First Previous page Previous … Page 7 Current page 8 Page 9 Page 10 … Next page Next Last page Last
